Objetivo Ocular neovascularization (NV) is the pathological feature common to Retinopathy of Prematurity, Diabetic Retinopathy, and Age-related Macular Degeneration. Collectively, these diseases are the leading cause of blindness in developed countries, and even more relevant due to the increased life expectancy. Current therapies can delay the progression of the disease, but do not restore the vision already lost. Therefore, there is a need for new, more efficient anti-angiogenic therapies. Gene therapy has been successfully used in several ocular disease paradigms. Most gene therapy strategies have used viral vectors due to their gene transfer efficiency. Nevertheless, viral vectors have several limitations, the most important ones the risk of random integration into the genome and potential severe immune response. Non-viral vectors have the potential to overcome the drawbacks associated with viral vectors but, to date, non-viral vectors still lag behind viral ones in gene transfer efficiency. This proposal aims to address both the need for new therapeutic strategies to treat ocular NV and development of new non-viral vectors optimized for ocular gene therapy. This dual approach would be feasible due to the multidisciplinary background of the Coordinator of this proposal in gene therapy, biology and and materials science. This project will study the potential of combining the inhibition of angiogenic factors and the expression of anti-angiogenic factors, delivered by the developed non-viral vectors. The outcome of this project would be two-fold: 1) non-viral vectors with an efficiency comparable to viral ones and 2) new therapeutic strategies to prevent loss of vision caused by the progression of ocular NV. This can significantly contribute to European excellence by decreasing the knowledge gap and generate added value products that can simultaneously have an economic impact but mostly have a social impact, specially in those ailing from diseases causing blindness Ámbito científico medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesbasic medicineimmunologymedical and health sciencesclinical medicineophthalmologyretinopathynatural sciencesbiological sciencesgeneticsgenomes Programa(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Tema(s) FP7-PEOPLE-2009-RG - Marie Curie Action: "Reintegration Grants" Convocatoria de propuestas FP7-PEOPLE-2009-RG Consulte otros proyectos de esta convocatoria Régimen de financiación MC-IRG - International Re-integration Grants (IRG) Coordinador UNIVERSIDADE DO ALGARVE Aportación de la UE € 100 000,00 Dirección CAMPUS DE PENHA 8005 139 Faro Portugal Ver en el mapa Región Continente Algarve Algarve Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo António Cabecinha (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos